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Objectives The aim of this study was to evaluate the safety and efficacy of the novel platinum chromium TAXUS Element
paclitaxel-eluting stent (PES) compared with the TAXUS Express PES (Boston Scientific, Natick, Massachusetts)
in treating coronary artery stenoses.
Background The TAXUS Element is a novel thin-strut (81 m), platinum chromium alloy PES designed to improve radial
strength, radiopacity, and deliverability, while safely providing comparable restenosis benefit compared with a
previous-generation PES.
Methods The PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS
Element Paclitaxel-Eluting Coronary Stent System) Workhorse (WH) trial is a prospective, randomized (3:1), con-
trolled, multicenter study of the TAXUS Element (vs. TAXUS Express) PES for the treatment of de novo coronary
atherosclerotic lesions 28 mm in length in reference vessels 2.75 to 4.0 mm in diameter. The primary end
point was the 12-month rate of target lesion failure, and the secondary end point was 9-month angiographic
in-segment percentage diameter stenosis. The study was powered to demonstrate noninferiority to TAXUS Ex-
press for both end points.
Results The intent-to-treat analysis included 1,262 patients (320 TAXUS Express, 942 TAXUS Element). The TAXUS Ele-
ment was noninferior to TAXUS Express with respect to both the incidence of target lesion failure (5.57% vs.
6.14%, respectively; difference: 0.57%; 95% credible interval: 1.85%; Bayesian posterior probability of noninferi-
ority  0.9996) and percentage diameter stenosis (ln[%DS] 3.09 vs. 3.12, respectively; difference: 0.03; 95%
credible interval: 0.11; Bayesian posterior probability of noninferiority  0.9970). No differences in clinical out-
comes to 12 months were observed between stent treatments, and stent thrombosis was infrequent (0.3% Ex-
press, 0.4% Element).
Conclusions At 1 year, the TAXUS Element is comparable in efficacy to the TAXUS Express PES. Furthermore, no safety con-
cerns related to the novel platinum chromium alloy or stent design were observed. (A Prospective Evaluation in
a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent
System for the Treatment of De Novo Coronary Artery Lesions; NCT00484315) (J Am Coll Cardiol 2010;56:
264–71) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.04.011
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July 20, 2010:264–71 Primary End Point Results: The PERSEUS WH Trialaclitaxel-eluting stents (PES) reduce clinical and angio-
raphic restenosis compared with bare-metal stents. The
AXUS Express (1,2) and TAXUS Liberté stents (3)
Boston Scientific, Natick, Massachusetts) have demonstrated
urable benefit across a broad spectrum of patient risk cohorts
1,4–7).
The TAXUS Element PES (Boston Scientific) incorpo-
ates a novel, thin-strut (81 m) platinum chromium metal
lloy (8) platform designed to enhance radiopacity, radial
trength, and conformability (Table 1). Although the poly-
er and drug are similar to those of prior TAXUS PES
latforms, the platinum chromium alloy has increased bend
atigue resistance, greater conformability, and increased
adial strength versus 316L stainless steel (Table 1). Because
latinum chromium is denser than 316L stainless steel (9),
adiopacity is enhanced despite thinner struts (10,11).
In pre-clinical testing, vascular compatibility was similar
mong bare-metal, polymer-only, and drug-coated Element
tents (10). Furthermore, strut coverage and endothelializa-
ion were more rapid in Element compared with the
xpress and Liberté stents (12).
The TAXUS PERSEUS (Prospective Evaluation in a
andomized Trial of the Safety and Efficacy of the Use of
he TAXUS Element Paclitaxel-Eluting Coronary Stent
ystem) Workhorse (WH) randomized clinical trial was
esigned to evaluate the safety and efficacy of the novel
hin-strut platinum chromium alloy TAXUS Element stent
ompared with the TAXUS Express stent in single de novo
oronary stenoses.
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evice description. The TAXUS
lement stent is laser-cut from
1-m platinum chromium alloy.
ontrolled slow release of pacli-
axel, incorporated at 1 g/mm2
nto poly(styrene-b-isobutylene-b-
tyrene) polymer is provided with
elease kinetics similar to those of
he previous generation TAXUS
xpress (2,6) and Liberté (3) 316L
tainless steel stent systems (11).
tudy design. The PERSEUS
H trial design has been re-
orted previously (11). The
ERSEUSWH trial is a prospec-
ive, randomized (3:1), single-
lind controlled trial powered
o evaluate noninferiority of the
AXUS Element compared
ith the TAXUS Express2 PES. Eligible subjects with a
ingle, native vessel, de novo target lesion of 50%
iameter stenosis with length 28 mm and reference
essel diameter 2.75 to 4.0 mm were enrolled be-
ween July 16, 2007, and October 1, 2008, at 90 clinical
ites (11). Randomization to treatment group was strat-
fied for the presence or absence of medically-treated
iabetes. Subjects (n  330) were randomly assigned to
-month quantitative coronary angiographic (QCA)
ollow-up throughout the course of trial enrollment. The
tudy primary end point is the rate of target lesion failure
TLF) (ischemia-driven target lesion revascularization
TLR], myocardial infarction [MI] related to target
essel, or cardiac death related to target vessel) at 12
onths after index procedure, and the key secondary end
oint is 9-month in-segment percentage diameter steno-
is by QCA. Clinical follow-up was scheduled at
0 days, 9 months, 12 months, 18 months, and annually
o 5 years.
Planned use of multiple stents was prohibited in both
reatment arms, and additional study stents in the target
esion were allowed only for suboptimal angiographic re-
ults, which compromised vessel integrity or threatened
essel closure (i.e., “bailout”). Treatment of 1 lesion in a
ontarget vessel during the index procedure was allowed
efore treatment of the target lesion, provided that nontar-
et lesion treatment was successful angiographically and did
ot require additional unplanned stents. Staged PCI or
ubsequent planned coronary artery bypass graft procedures
ere not allowed. Other inclusion and exclusion criteria
ave been reported (11).
Thienopyridine treatment was required by protocol for at
east 6 months, preferably to 12 months, in subjects not at
Abbreviations
and Acronyms
DS  diameter stenosis
FDA  Food and Drug
Administration
MACE  major adverse
cardiac events
MI  myocardial infarction
MLD  minimal lumen
diameter
PES  paclitaxel-eluting
stent
QCA  quantitative
coronary angiography
TLF  target lesion failure
TLR  target lesion
revascularization
TVR  target vessel
revascularizationigh risk of bleeding (13), and daily aspirin therapy was
TP
c
S
T
a
s
m
f
L
of a deployed stent by 15%. Measured with 2.5-mm stents (n  3 TAXUS Express, n  15 TAXUS Liberté, n  15 TAXUS Element).
LV  large vessel; SV  small vessel; SWH  small workhorse; WH  workhorse.
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Primary End Point Results: The PERSEUS WH Trial July 20, 2010:264–71Figure 1 PERSEUS WH Study Flow
Patients included in the intent-to-treat PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary
Stent System) Workhorse (WH) clinical and angiographic analyses. *Includes 2 TAXUS Express patients and 6 TAXUS Element (Boston Scientific) patients who died before the 12-month
follow-up visit. †Includes 1 TAXUS Express patient and 2 TAXUS Element patients with follow-up angiography 15 days after procedure, 1 TAXUS Element patient with follow-up angiogra-
phy 395 days after procedure, and 1 TAXUS Express patient with angiography 120 days after procedure and no TVR 395 days. QCA  quantitative coronary angiography.AXUS Stent CharacteristicsTable 1 TAXUS Stent Characteristics
Component/Characteristic TAXUS Express TAXUS Liberté TAXUS Element Impact of Change
Stent material 316L stainless steel 316L stainless steel Platinum chromium alloy Higher strength & radiopacity
Drug Paclitaxel N/A
Polymer Slow-release translute polymer N/A
Strut thickness, m 132 97 81–86* Greater flexibility
Lower profile
Reduced inflammation
Surface-to-artery ratio, %† 11.1–16.7 11.8–15.8 12.4–15.1 More uniform drug delivery
across stent diameters
Stent models 2 (WH, LV) 3 (SV, WH, LV) 4 (SV, SWH, WH, LV)
Material density, g/ml‡ 8 8 9.9 Increased radiopacity
Nickel content, %§ 14 14 9 Reduced hypersensitivity
Challenge focal bend fatigue, millions 0.03 0.37 9.19 Fracture resistance
Pulsatile radial fatigue, millions¶ 400 400 400
Conformability, N/mm# 0.34 0.09 0.04 Flexibility
Radial strength, N/mm** 0.23 0.24 0.26 Compression resistance
ortions of data reproduced from Allocco et al. (11). *Strut thickness is 86 m for the 4.00-mm model and 81 m for all other models. †Surface-to-artery ratio (SAR) is the percentage of artery wall area
overed by outer surface area of the stent. Large values imply a greater surface area of drug coating in direct contact with the vessel and, by inference, a larger dose delivered to the local arterial tissue.
AR can vary significantly by diameter for the same stent model. Increasing the number of stent models covering a diameter range decreases the variation of SAR by minimizing the stent’s working range.
he SAR was calculated on the basis of stent design prints (16-mm length bare-metal stents). Ranges from 2.25- to 4.0-mm stents are shown. ‡Measured in accordance with American Society for Testing
nd Materials standards (9). §Nominal elemental composition by weight (%). Focal bend challenge test, as measured by an accelerated life test of the bending fatigue of a stent in a simulated overlapped
tent configuration, showing number of bend cycles before stent fracture. The test is conducted by mounting 1 end of a nominally deployed stent to a fixed mandrel while the other end is mounted to a
andrel suspended in a flexible membrane. The membrane-mounted end of the stent is translated perpendicular to the longitudinal axis of the stent to impart a repeatable bend in the stent. ¶Pulsatile
atigue test, all stents demonstrate no failure to 400 cycles. #Conformability—a measure of the torque required to bend the stent to a specific curvature, which is directly related to flexibility of the stent.
ower required bending moment indicates increased flexibility; n  4 Express, n  10 Liberté, n  15 Element. **Measures the radial force, normalized by stent length, required to reduce the diameter
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July 20, 2010:264–71 Primary End Point Results: The PERSEUS WH Trialequired indefinitely. Other periprocedural adjunctive phar-
acotherapy was administered per standard practice of the
articipating institution (11).
The study protocol was approved by all participating
thics review committees, and all patients provided written
nformed consent. An independent clinical events commit-
ee adjudicated all stent thrombosis and major adverse
ardiac events (MACE). An independent data monitoring
ommittee provided oversight of aggregate safety data.
entral core laboratory analysis of all angiographic stud-
es was performed by the CardioVascular Institute at
eth Israel Deaconess Medical Center (Boston, Massa-
husetts) with standard qualitative morphologic criteria
imilar to those used in the TAXUS Express and Liberté
linical trials (14).
tatistical methods. Bayesian hierarchical modeling was
sed for the primary and key secondary end points, and
odeling analyses (15) based on the per-protocol analysis
ohort (excluding patients who did not receive the assigned
tudy stent). For all other analyses, the intent-to-treat
andomized treatment groups were compared with frequen-
ist analysis methods with a Student t test for continuous
easures and a chi-square or Fisher exact test for discrete
easures. Historical data from the TAXUS IV and V
tudies (2,6) were used in sample size calculations (11).
rior data were to be borrowed under the Bayesian frame-
ork only if the observed 12-month TLF rate in the
ERESUS WH randomized TAXUS Express control
roup was 8.0%. Because the observed TLF rate in this
roup was only 6.1%, prior data were not borrowed for
ither the primary or secondary end point analyses in order
o maintain a more conservative approach. For the second-
ry end point, a natural log (ln) transformation was used on
he data to improve the normality of the distribution;
nalyses were performed on the transformed data. Nonin-
eriority margins () of 4.1% and 0.20 were used for the
rimary and secondary end point analyses, respectively.
oninferiority of the TAXUS Element stent is accepted if
he Bayesian posterior probability is at least 95% that the
ifference in 12-month TLF or ln(percentage diameter
tenosis) between TAXUS Element and TAXUS Express
as less than the pre-specified . In this Bayesian
pproach, the posterior probability of noninferiority is
imilar to the complement of the p value used in the
requentist approach.
A sample size of 1,264 subjects was expected to provide
,200 evaluable subjects (assuming 5% attrition) and was
etermined through simulations based on hierarchical mod-
ling as well as discussions with the U.S. Food and Drug
dministration (FDA). Although power and type I error do
ot apply to the PERSEUS WH trial in the frequentist
ense, this sample size is the minimum sample size required
o give approximately an 80% probability of correctly con-
luding noninferiority (over a range of assumed TAXUS dxpress TLF rates from 6% to 12%), under the assumption
hat TAXUS Element was noninferior to TAXUS Express.
To assess the validity of pooling across clinical sites in the
ERSEUSWH trial, a frequentist logistic regression model
as used to test the site  treatment interaction on the
rimary TLF end point (p  0.99).
Multivariate modeling methods are described in Online
ppendix A. Statistical methodology and software pro-
rams used in the PERSEUS WH trial have been detailed
reviously (11).
esults
aseline demographic data and lesion characteristics.
igure 1 depicts patients included in the 9-month QCA and
2-month clinical follow-up. A total of 1,262 patients were
ncluded in the intent-to-treat analysis set (320 TAXUS
xpress, 942 TAXUS Element) with 97.7% 12-month
linical follow-up and 87.6% 9-month angiographic follow-
p. Baseline demographic and lesion characteristics are
hown in Table 2. No differences between randomized stent
aseline Patient Demographic Datand Lesion CharacteristicsTable 2 B seline Patient Demographic Dataand Lesion Characteristics
TAXUS Express
(n  320)
TAXUS Element
(n  942) p Value
Demographic data, cardiac
history, and risk factors
Age, yrs 63.5 9.5 (320) 62.2 9.6 (942) 0.03
Male 68.8 (220/320) 70.8 (667/942) 0.49
Unstable angina 21.3 (68/320) 20.7 (195/941) 0.84
Silent ischemia 12.2 (39/320) 12.4 (117/941) 0.91
Ejection fraction 57.8 9.8 (317) 58.0 9.3 (939) 0.73
Prior MI 19.0 (60/316) 20.9 (195/935) 0.48
Prior congestive heart
failure
7.5 (24/318) 6.0 (56/937) 0.32
Smoker (current) 23.5 (73/311) 24.3 (223/916) 0.76
Caucasian race 92.5 (296/320) 92.6 (872/942) 0.97
Medically treated diabetes 25.0 (80/320) 24.6 (232/942) 0.89
Insulin-requiring 7.5 (24/320) 7.3 (69/942) 0.92
Hyperlipidemia* 76.4 (243/318) 76.3 (717/940) 0.96
Hypertension* 80.3 (256/319) 75.3 (709/941) 0.07
Target lesion characteristics
by QCA
LAD target vessel 43.8 (140/320) 43.1 (406/942) 0.84
Reference vessel diameter 2.75 0.47 (320) 2.78 0.48 (942) 0.37
Minimal lumen diameter 0.79 0.35 (320) 0.77 0.34 (942) 0.62
% diameter stenosis 71.7 10.9 (320) 72.1 10.9 (942) 0.58
Target lesion length, mm 14.1 5.8 (320) 14.2 6.1 (942) 0.68
Modified ACC/AHA B2 or C 64.7 (207/320) 66.9 (630/942) 0.47
Tortuosity (moderate or
severe)
4.4 (14/320) 6.3 (59/942) 0.21
Calcification (moderate or
severe)
26.9 (86/320) 24.2 (228/942) 0.34
Bifurcation lesions 40.3% (129/320) 36.4% (343/942) 0.21
alues are % (n/N) or mean  SD (n). *Requiring medication.
ACC/AHA  American College of Cardiology/American Heart Association; LAD  left anterior
escending artery; MI  myocardial infarction; QCA  quantitative coronary angiography.
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Primary End Point Results: The PERSEUS WH Trial July 20, 2010:264–71reatment groups were observed, with the exception that
AXUS Element stent-treated subjects were slightly
ounger.
echnical and procedural performance. Technical suc-
ess (successful delivery and deployment of the study stent
ithout balloon rupture or stent embolization) was compa-
able between treatment groups (Table 3). Other procedural
haracteristics including use of multiple stents, stent length/
esion length ratio, maximum deployment pressure, use of
ost-dilation, and maximum post-dilation pressures were all
imilar between randomized treatment groups (Table 3).
ntiplatelet medication compliance. Aspirin and thien-
pyridine use at 12 months after the procedure was similar
or TAXUS Express- and Element-treated patients (aspirin
7.4% vs. 96.4%, respectively, and thienopyridine 91.3% vs.
echnical and Procedural PerformanceTable 3 Technical and Procedural Performance
TAXUS
(n  320 Patie
Stent-based technical performance in all attempted
study stents (per stent)
Technical success (per stent)* 98.8% (
Technical failure (per stent) 1.2 (
Unable to cross lesion 0.9 (
Balloon rupture 0.0 (
Stent embolization 0.0 (
Other 0.3 (
Withdrawal resistance 0.3% (
Other delivery system failure 0.6 (
Clinical procedural performance (per patient)
Clinical procedural success‡ 97.2 (
Clinical procedural failure 2.8 (
In-hospital MACE 2.5 (
Post-procedure % diameter stenosis 30% 0.3 (
Post-procedure TIMI flow grade 3 0.0 (
Index procedure characteristics (per patient)
Procedure time, min§ 18.6 1
Total fluoroscopy time, min 10.0 8
Stent/lesion length ratio (QCA) 1.60 0
Multiple stents implanted 8.4 (
Total stent length implanted, mm 21.1 9
Post-dilation 53.8 (
Maximum deployment pressure, overall, atm 16.0 3
Study stent inflation pressure 14.0 2
Post-dilation pressure 16.6 3
Post-procedure outcomes
Post-procedure MLD (QCA), mm
Analysis segment 2.16 0
In-stent 2.54 0
Acute gain (QCA), mm
Analysis segment 1.45 0
In-stent 1.83 0
alues are % (n/N) or mean  SD (n). *Technical success is defined as successful delivery and de
elivery system failure consisted of 1 instance of proximal strut lifting (TAXUS Element), 1 instance
tent had both a withdrawal resistance and a stent recoil and is thus counted only once in the total.
nfarction (TIMI) flow grade 3, as visually assessed by the physician, without the occurrence of in-
MACE major adverse cardiac events (target-vessel related myocardial infarction, cardiac deat1.6%, respectively). iCA results. Post-procedural QCA demonstrated a sig-
ificant increase in in-stent minimal lumen diameter
MLD) for TAXUS Element compared with TAXUS
xpress stent-treated patients, which was supported by
umerically increased in-stent acute gain, despite similar
eployment and post-dilational pressures between stent
reatment groups (Table 3).
Angiographic measures including MLD, percentage di-
meter stenosis, late loss (in-stent and in-segment), and
inary (50%) restenosis were all similar between QCA-
ubset treatment groups (Table 4). For the key secondary
tudy end point of in-segment percentage diameter stenosis
t 9 months, with a pre-specified margin of 0.20, the
osterior probability of noninferiority was 99.7% (Fig. 2B),
eeting the secondary end point.
Two TAXUS Element stent fractures (0.64%) were
ss
42 Stents)
TAXUS Element
(n  942 Patients, 1,013 Stents) p Value
42) 99.2% (1,005/1,013) 0.51
) 0.8 (8/1,013) 0.51
) 0.4 (4/1,013) 0.38
) 0.0 (0/1,013) —
) 0.0 (0/1,013) —
) 0.4 (4/1,013) 0.99
) 0.1% (1/1,006) 0.44
)† 0.1 (1/1,006)† 0.16
20) 97.6 (919/942) 0.72
) 2.4 (23/942) 0.72
) 1.9 (18/942) 0.52
) 0.5 (5/942) 0.99
) 0.3 (3/942) 0.58
18) 17.4 10.0 (936) 0.07
9) 9.9 7.2 (936) 0.95
19) 1.55 0.64 (940) 0.25
0) 7.6 (72/942) 0.65
9) 20.6 8.2 (940) 0.39
20) 53.6 (505/942) 0.97
9) 15.9 3.1 (941) 0.60
6) 13.7 2.4 (932) 0.15
2) 16.6 3.6 (506) 0.95
1) 2.25 0.49 (228) 0.17
1) 2.68 0.39 (228) 0.01
1) 1.51 0.48 (228) 0.41
1) 1.93 0.41 (228) 0.09
nt of the study stent to the target vessel, without balloon rupture or stent embolization. †”Other”
recoil (TAXUS Express), and 1 instance of a mechanical kink (TAXUS Express). One TAXUS Express
lesion diameter stenosis30% in 2 near-orthogonal projections with Thrombolysis In Myocardial
l MACE. §Time from last pre-dilation to last guide catheter removal (min).
get vessel revascularization); MLD minimal lumen diameter; other abbreviations as in Table 2.Expre
nts, 3
338/3
4/342
3/342
0/342
0/342
1/342
1/338
2/338
311/3
9/320
8/320
1/320
0/320
1.9 (3
.6 (31
.73 (3
27/32
.1 (31
172/3
.0 (31
.8 (31
.3 (17
.37 (6
.36 (6
.40 (6
.40 (6
ployme
of stent
‡Meandentified by the core laboratory among the 314 implanted
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July 20, 2010:264–71 Primary End Point Results: The PERSEUS WH Trialtents in 294 patients of the randomized QCA subset (16).
o fractures were observed in TAXUS Express study stents.
o additional fractures were identified from among all
vailable films (including non–QCA-subset patients who
eceived angiography). There were no in-stent restenoses or
neurysms associated with either fractured stent, and neither
atient experienced MACE or stent thrombosis events
hough 12-month follow-up.
linical outcomes. The primary study end point of TLF
o 12 months after procedure was similar between the
andomly assigned stent platforms (5.57% TAXUS Ele-
ent vs. 6.14% TAXUS Express; difference 0.57%; 95%
redible interval: 1.85%) (Figs. 2A and 3). With a pre-
pecified margin of 4.1%, the Bayesian posterior probability
f noninferiority was 99.96%, meeting the primary end
oint. Bayesian multivariate analysis demonstrated that use
f unplanned stents and smaller final in-segment MLD was
ssociated with an increased risk of TLF to 12 months
Online Appendix A). After adjustment for covariate pre-
ictors, the Bayesian posterior probability of noninferiority
or TLF was maintained at 95.47%.
Additional 12-month clinical end points are shown in
able 5 (17). No differences in the rates of MACE,
ortality (cardiac or noncardiac), revascularization, or stent
hrombosis were observed between treatment groups. Al-
hough the overall incidence of MI was similar between
tent types, non–Q-wave MI was numerically less frequent
fter TAXUS Element (1.6% vs. 2.9% TAXUS Express),
CA Outcomes at 9 MonthsPaired Lesion Analyses)Table 4 QC Outcomes at 9 Months(Paired Lesion Analyses)
TAXUS Express
(n  74)
TAXUS Element
(n  256) p Value
Minimal lumen diameter, mm
Analysis segment* 2.00 0.56 (61) 2.08 0.63 (228) 0.37
In-stent 2.28 0.64 (61) 2.34 0.67 (228) 0.51
% diameter stenosis
Analysis segment* 26.37 17.47 (61) 26.10 17.71 (228) 0.92
In-stent 16.02 20.61 (61) 16.37 20.86 (228) 0.91
Late loss, mm
Analysis segment* 0.16 0.45 (61) 0.17 0.48 (228) 0.86
In-stent 0.26 0.52 (61) 0.34 0.55 (228) 0.33
Binary restenosis, %
Analysis segment* 9.8 (6/61) 8.8 (20/228) 0.80
Proximal edge† 3.4 (2/59) 1.4 (3/220) 0.29
In-stent† 6.6 (4/61) 7.9 (18/228) 0.99
Distal edge† 0.0 (0/60) 1.8 (4/227) 0.58
ISR characteristics
Focal 25.0 (1/4) 44.4 (8/18) 0.62
Diffuse 50.0 (2/4) 33.3 (6/18) 0.60
Proliferative 0.0 (0/4) 16.7 (3/18) 0.99
Total occlusion 25.0 (1/4) 5.6 (1/18) 0.34
ISR length, mm 14.13 9.40 (4) 14.28 8.94 (18) 0.98
alues are % (n/N) or mean  SD (n). *The analysis segment consists of the proximal edge, the
tent, and the distal edge, where each edge segment contains up to 5mm immediately outside the
tent. †Multiple events/patient are counted only once in the analysis segment rate.
ISR  in-stent restenosis; QCA  quantitative coronary angiography.riven by fewer periprocedural infarctions.iscussion
he PERSEUS WH trial provides the necessary assurance
f safety and relative efficacy of the novel platinum chro-
ium TAXUS Element PES platform, demonstrating non-
nferiority to the TAXUS Express PES with respect to the
ncidence of TLF at 12 months and the severity of residual
ngiographic stenosis at 9 months. These results were
emonstrated within the framework of a Bayesian study
esign, which has been accepted by the FDA for medical
evice clinical trials (15) and might be considered a more
ntuitive and clinically meaningful method of analysis than
he conventional frequentist approach (18).
Studies have suggested that bare-metal stents with thin-
er struts might provide reduced late loss compared with
hicker-strut stents (19,20). Although this finding was not
Figure 2 PERSEUS WH Primary and Secondary End Points
Based on a per-protocol analysis set, which excludes patients who did not
receive the assigned study stent (n  315 TAXUS Express, 933 TAXUS Ele-
ment). (A) PERSEUS WH primary end point, 12-month target lesion failure (TLF)
(ischemia-driven target lesion revascularization, or target-vessel–related
myocardial infarction or cardiac death). (B) PERSEUS WH secondary end
point, ln(%DS [percentage diameter stenosis]) at 9 months. Abbreviations
as in Figure 1.
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ollowing points deserve mention. First, the increase in
cute gain observed after TAXUS Element (vs. TAXUS
xpress) on post-procedural QCA would be expected to be
ccompanied by a greater late lumen loss in follow-up. The
Figure 3 TLF to 12 Months
Cumulative rate of target lesion failure (TLF) to 12 months, event rate  1.5 SEM
linical Outcomes at 12 MonthsFrequentist Analysis)Table 5 Clinical Outcomes at 12 Months(Frequentist Analysis)
TAXUS Express
(n  320)
TAXUS Element
(n  942) p Value
TLF* 6.1 (19/313) 5.6 (52/922) 0.78
MACE† 7.7 (24/313) 7.4 (68/922) 0.86
Cardiac death or MI 2.9 (9/313) 2.5 (23/922) 0.71
Cardiac death 0.3 (1/313) 0.5 (5/922) 0.99
MI‡ 2.9 (9/313) 2.2 (20/922) 0.48
Q-wave MI 0.0 (0/313) 0.5 (5/922) 0.34
Non–Q-wave MI§ 2.9 (9/313) 1.6 (15/922) 0.17
TVR, overall 5.8 (18/313) 5.6 (52/922) 0.94
TLR, overall 4.5 (14/313) 3.8 (35/922) 0.60
TLR, PCI 4.2 (13/313) 3.6 (33/922) 0.64
TLR, CABG 0.6 (2/313) 0.3 (3/922) 0.61
Non-TLR, overall 1.9 (6/313) 2.5 (23/922) 0.56
Non-TLR, PCI 1.6 (5/313) 2.3 (21/922) 0.47
Non-TLR, CABG 1.0 (3/313) 0.3 (3/922) 0.17
All-cause mortality 0.6 (2/314) 0.7 (6/922) 0.99
Stent thrombosis 0.3 (1/313) 0.4 (4/918) 0.99
Acute (0–1 days) 0.3 (1/320) 0.2 (2/942) 0.99
Subacute (2–30 days) 0.0 (0/319) 0.0 (0/939) —
Late (31–365 days) 0.0 (0/317) 0.2 (2/936) 0.99
alues are % (n/N). *Target lesion failure (TLF) is defined as any ischemia-driven revascularization
f the target lesion (TLR), myocardial infarction (MI) related to the target vessel, or cardiac death
elated to the target vessel. †MACE (major adverse cardiac events) is defined as MI, target vessel
evascularization (TVR), or cardiac death. ‡MI is defined as Q-wave MI (de novo Q waves in 2 or
ore leads lasting 0.04 s, with elevated creatine kinase myocardial band [CK-MB]) or non–Q-
ave MI (de novo elevation of CK 2.0 upper limit of normal without new Q waves or positive
K-MB). §Timing of non–Q-wave MI: 8 of 9 TAXUS Express events and 15 of 15 TAXUS Element
vents occurred periprocedurally. Stent thrombosis was adjudicated by the clinical events
ommittee according to the Academic Research Consortium (ARC) definite/probable definition
22) and does not exclude events occurring before or after TLRs.e
CABG coronary artery bypass graft; PCI percutaneous intervention; other abbreviations as in
ables 2 and 3.haracteristic direct relationship between acute gain and late
oss is demonstrated by the comparison of TAXUS Element
ith TAXUS Express and results in similar net gain as
eflected by the incidence of binary angiographic restenosis.
econd, the noninferiority study design was not powered to
etect statistically significant differences between the 2
rug-eluting stent arms. Finally, the potential impact of
educed strut thickness on late lumen loss might be over-
ome by the relative impact of drug and polymer.
Importantly, no safety concerns were observed in the
ourse of the trial. Although the study is underpowered for
ow-frequency events and the current duration of follow-up
s limited (1 year), the incidence of death, MI, and stent
hrombosis was low and similar between randomly assigned
tent platforms. Only 2 stent fractures were noted in the
tudy (0.64%), consistent with fracture rates in other PES.
o adverse clinical events, in-stent restenoses, or aneurysms
ere associated with these fractures.
The ischemia-driven TLR rate in the nonangiographic
ohort of the PERSEUS TAXUS Express control (3.4%)
ompares favorably to that observed in TAXUS Express-
reated patients enrolled into the SPIRIT IV trial (4.5%)
21). Ischemia-driven TLR rates were numerically lower in
he nonangiographic cohort of TAXUS Element patients in
he PERSEUS trial (2.8%) and in everolimus-eluting stent-
reated patients in the SPIRIT IV trial (2.3%). The TLR
ates in the nonangiographic cohort of the ENDEAVOR
V study were 3.6% for zotarolimus-eluting stents and 3.2%
or PES (22). Thus, the TAXUS Element PES seems to
rovide similar clinical efficacy to other available paclitaxel-
r rapamycin-derived drug-eluting stents.
tudy limitations. A potential limitation of the PERSEUS
H trial is that the control stent comparator is the
rst-generation TAXUS Element PES (1), which was the
nly commercially available PES in the U.S. at the time
tent-to-treat patients (n  1,262)., all innrollment into the PERSEUS WH trial was initiated.
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July 20, 2010:264–71 Primary End Point Results: The PERSEUS WH Trialevertheless, the safety and efficacy parameters observed
fter TAXUS Element in the PERSEUS WH trial com-
are favorably with those observed after deployment of the
ore recently FDA-approved TAXUS Liberté PES in
he TAXUS ATLAS (A Multi-Center, Single-Arm Study
f the TAXUS Liberté-SR Stent for the Treatment of
atients With de Novo Coronary Artery Lesions) trial (3).
onclusions
he PERSEUS WH randomized clinical trial demonstrates
omparable efficacy between the novel platinum chromium
lloy TAXUS Element PES and the TAXUS Express PES.
mportantly, no safety concerns regarding either the novel
etal alloy or modified stent design were observed. The
ERSEUS WH trial demonstrates successful transfer of PES
echnology from stainless steel to a platinum chromium alloy
latform.
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